2026 oncology meetings
SITC, ESMO, ASCO, AACR and ASH 2026. 285 abstracts found by web research and verified against a source page so far, plus each meeting's journal supplement searched live through Crossref where it is indexed. Titles and metadata only.
SITC
SITC Annual Meeting 2026
4–8 Nov 2026, Phoenix
18
verified abstracts in 1 area
ESMO
ESMO Congress 2026
23–27 Oct 2026, Madrid
146
verified abstracts in 8 areas
ASCO
ASCO Annual Meeting 2026
29 May – 2 Jun 2026, Chicago
13
verified abstracts in 1 area
AACR
AACR Annual Meeting 2026
17–22 Apr 2026, San Diego
10
verified abstracts in 1 area
ASH
ASH Annual Meeting 2026
12–15 Dec 2026, New Orleans
98
verified abstracts in 4 areas
175 of 285 verified abstracts were confirmed on a page we fetched ourselves
Verified abstracts per 2026 meeting, split by how each row was checked. The rest match the text Parallel saved from a page that blocks automated access, mostly ESMO's congress platform.
Found on the cited source pageFound on a second fetched pageMatches only the excerpt saved from a page we could not re-fetch
Rows that failed every check were dropped and are not counted. Source: data/meetings in the project repository, each row linked to its source page.
SITC Annual Meeting 2026
4–8 Nov 2026, Phoenix · Journal for ImmunoTherapy of Cancer 14 (Suppl 2 and 3), open access
1,109 regular and 19 late-breaking abstracts are in Crossref as open-access JITC supplement records (CC BY-NC); the supplement may still be filling in.
Late-breaking, across tumour types
18 verified · pulled 2026-11-11 · showing 0 headline abstractsAll SITC abstracts →- 488Poster
- 603PosterMulti-omics analyses reveal intratumoral and systemic immune activation to aglatimagene besadenovec+valacyclovir related to improved survival in patients with progressive NSCLC despite ICI treatmentaglatimagene besadenovecvalacyclovirVerified on source pageir.candeltx.com
- 1174PosterPeripheral immune correlates of denileukin diftitox-cxdl plus pembrolizumab in heavily pretreated recurrent or advanced gynecologic malignanciesRobert Edwardsdenileukin diftitox-cxdlpembrolizumabVerified on source pagesitcancer.org
- 1176Poster
- 1179Poster
- 1180PosterInterim safety and efficacy results of Victoria-01: A phase 1 study to evaluate the safety and preliminary efficacy of SOT201 in patients with advanced/metastatic solid tumorsAung NaingVictoria-01SOT201Verified on source pagesitcancer.org
ESMO Congress 2026
23–27 Oct 2026, Madrid · Annals of Oncology, vol. 37 supplement
The ESMO 2026 abstract supplement was not in Crossref on 11 Nov 2026 and ESMO's congress platform blocks automated access, so ESMO abstracts here come from web research: each row was found on a published congress report and verified against it.
Breast cancer
33 verified · pulled 2026-11-11 · showing 6 headline abstractsOpen in Breast cancer →All ESMO abstracts →- LBA14Late-breakingA double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for HER-2 negative and estrogen receptor positive (ER+) metastatic breast cancer (MBC): Overall survival results of the CCTG/BCT MA.40/FINER studyAndrew D. RedfernCCTG/BCT MA.40/FINERfulvestrantipatasertibMatches source excerptcslide.ctimeetingtech.com
- LBA15Late-breakingAnbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III studyBinghe Xuanbenitamabalbumin-bound docetaxelMatches source excerptcslide.ctimeetingtech.com
- LBA16Late-breakingVIKTORIA-1: Updated results of a randomized, open-label, phase 3 study of gedatolisib (geda) + fulvestrant (fulv) ± palbociclib (palbo) vs standard of care in patients (pts) with HR+/HER2- advanced breast cancer (ABC) (Study 2)Barbara PistilliVIKTORIA-1gedatolisibfulvestrantpalbociclibMatches source excerptcslide.ctimeetingtech.com
- LBA17Late-breakingHER2-PET imaging to predict trastuzumab deruxtecan (T-DXd) efficacy in advanced breast cancer: The phase II PREDICT-HER trialJuan JinPREDICT-HERtrastuzumab deruxtecan (T-DXd)Matches source excerptcslide.ctimeetingtech.com
- LBA23Late-breaking
- LBA24Late-breakingFinal analysis of NRG oncology/NSABP B-42, a randomized, double-blinded, placebo-controlled trial of extended letrozole in postmenopausal women with hormone-receptor positive breast cancer who have completed previous adjuvant therapy with an aromatase inhibitorMatches source excerptcslide.ctimeetingtech.com
Colorectal cancer
11 verified · pulled 2026-11-11 · showing 6 headline abstractsOpen in Colorectal cancer →All ESMO abstracts →- LBA29Late-breaking
- LBA30Late-breaking
- LBA31Late-breakingBiweekly versus conventional trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer: The pragmatic phase 3 PRABITAS trialHiroya TaniguchiPRABITAStrifluridine/tipiracilbevacizumabMatches source excerptcslide.ctimeetingtech.com
- LBA32Late-breaking
- LBA87Late-breaking
- 3530OOral presentation
Glioblastoma and adult gliomas
21 verified · pulled 2026-11-11 · showing 3 headline abstractsOpen in Glioblastoma →All ESMO abstracts →- 692OOral presentation
- 693OOral presentation
- 694OOral presentation
Non-small cell lung cancer
62 verified · pulled 2026-11-11 · showing 6 headline abstractsOpen in Non-small cell lung cancer →All ESMO abstracts →- LBA5Presidential
- LBA6Presidential
- LBA62Late-breaking
- LBA64Late-breakingToripalimab plus chemotherapy as perioperative treatment for resectable stage II or III non-small cell lung cancer (NSCLC): Final analysis of the Phase 3 Neotorch studyShun LuNeotorchtoripalimabchemotherapyVerified on a second sourceliangyihui.net
- LBA65Late-breaking
- LBA66Late-breakingSacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus chemotherapy (chemo) plus pembrolizumab (P) as first-line (1L) treatment for PD-L1 negative advanced non-squamous (nsq) NSCLC: randomized phase 3 OptiTROP-Lung06 studyCaicun ZhouOptiTROP-Lung06sacituzumab tirumotecanpembrolizumabchemotherapyVerified on a second sourceliangyihui.net
Pancreatic cancer
17 verified · pulled 2026-11-11 · showing 4 headline abstractsOpen in Pancreatic cancer →All ESMO abstracts →- LBA82Late-breaking
- LBA83Late-breakingSeven-valent mKRAS-specific lymph node targeted amphiphile immunotherapy versus observation in resected pancreatic ductal adenocarcinoma (PDAC): The AMPLIFY-7P randomized phase 2 studyEileen M. O'ReillyAMPLIFY-7PELI-002 7PMatches source excerptcslide.ctimeetingtech.com
- LBA33Mini oral
- LBA85Mini oral
- 4457PPoster
ASCO Annual Meeting 2026
29 May – 2 Jun 2026, Chicago · Journal of Clinical Oncology 44 (16_suppl; LBAs in 17_suppl)
All 7,222 regular abstracts and 60 late-breaking abstracts have JCO supplement DOIs in Crossref.
Non-small cell lung cancer
13 verified · pulled 2026-11-11 · showing 6 headline abstractsOpen in Non-small cell lung cancer →All ASCO abstracts →- LBA4PresidentialIvonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial.Chen Zhiwei (presented by Shun Lu, MD, PhD)HARMONi-6NCT05840016ivonescimabtislelizumabpaclitaxelcarboplatinVerified on source pageasco.org
- LBA1510Late-breakingLow-dose pembrolizumab with chemotherapy in advanced NSCLC: A phase 3 randomized trial.Nandini Sharrel Menon (presented by Nandini Sharrel Menon, MD, DNB, MBBS)pembrolizumabpemetrexedpaclitaxelcarboplatinVerified on source pageasco.org
- LBA8500Late-breaking
- 8000Oral presentation
- 8001Oral presentation
- 8002Oral presentationNeoadjuvant lorlatinib in stage III NSCLC harboring ALK fusion: A phase 2 multicenter study (LORIN).LORINlorlatinibVerified on a second sourceascopubs.org
AACR Annual Meeting 2026
17–22 Apr 2026, San Diego · Cancer Research 86 (7_Supplement)
All 7,489 abstracts, including clinical trial (CT) and late-breaking (LB) abstracts, have Cancer Research supplement DOIs in Crossref.
Non-small cell lung cancer
10 verified · pulled 2026-11-11 · showing 6 headline abstractsOpen in Non-small cell lung cancer →All AACR abstracts →- CT014Oral presentation
- CT015Oral presentationClinical outcomes by genomic markers and ctDNA dynamics with perioperative nivolumab (NIVO) for resectable NSCLC from CheckMate 77TBohnetCheckMate 77TnivolumabVerified on source pageaacrjournals.org
- CT020Oral presentation
- CT021Oral presentation
- CT038Oral presentation
- CT231Oral presentation
ASH Annual Meeting 2026
12–15 Dec 2026, New Orleans · Blood 148 (Supplement 1)
The meeting is in December. Regular abstracts have been public since 4 Nov 2026 but the Blood supplement was not in Crossref on 11 Nov, so ASH abstracts here come from web research. Late-breaking abstracts are embargoed until 7 Dec and are not shown.
Acute myeloid leukemia
16 verified · pulled 2026-11-11 · showing 6 headline abstractsOpen in Acute myeloid leukemia →All ASH abstracts →- 228Oral presentation
- 386Oral presentation
- 388Oral presentationRevumenib as pre-emptive therapy for measurable residual disease in NPM1 mutated or KMT2A-rearranged AML: Update from the ALLG AMLM26 intercept platform trialALLG AMLM26 interceptrevumenibVerified on source pageonlineprogram.hematology.org
- 502Oral presentationMeasurable residual disease detection by RT-qPCR for pediatric acute myeloid leukemiaAnushka Walia, MDVerified on source pageonlineprogram.hematology.org
- 661Oral presentation
- 662Oral presentationAzacitidine, venetoclax, and revumenib in newly diagnosed NPM1-mutated (NPM1m) or KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML): Final analysis of beat AML phase 1b studyJoshua F. Zeidner, MDbeat AMLazacitidinevenetoclaxrevumenibVerified on source pageonlineprogram.hematology.org
Chronic myeloid leukemia
29 verified · pulled 2026-11-11 · showing 6 headline abstractsOpen in Chronic myeloid leukemia →All ASH abstracts →- 91Oral presentation
- 92Oral presentation
- 93Oral presentationAdditional somatic mutations detected by serial single-molecule molecular inversion probe sequencing in a prospective cohort of newly diagnosed chronic myeloid leukemia: Insights on mutational dynamics from the prospective TCGA-GTA registryMaria Perusini, MD, MscVerified on source pageonlineprogram.hematology.org
- 94Oral presentationImmune surveillance after a second TKI stop in CML: Dasatinib-associated CD4+ T-cell modulation and tfr duration — first findings from the DASTOP2 studyPakize Ak, MSDASTOP2dasatinibVerified on source pageonlineprogram.hematology.org
- 95Oral presentationFrontline therapy with tyrosine kinase inhibitors (TKIs) may modify the frequency of mutated ASXL1 and the cell lineage in blast Phase (BP) CML: Insights from the international CML foundation (iCMLf) genomics alliance on the Harmony PlatformSusan Branford, PhDVerified on source pageonlineprogram.hematology.org
- 96Oral presentationLongitudinal myeloid-panel sequencing reveals a diverse spectrum of somatic mutation dynamics in asciminib-treated chronic myeloid leukemiaAna Flavia Patiño IV, MDasciminibVerified on source pageonlineprogram.hematology.org
Other leukemias (ALL, CLL)
23 verified · pulled 2026-11-11 · showing 6 headline abstractsAll ASH abstracts →- 254Oral presentation
- 255Oral presentation
- 256Oral presentation
- 257Oral presentation
- 258Oral presentationBCL2 mutations other than G101V dominate the landscape of venetoclax-resistance mutations in CLL treated in the current eraConstantine S. Tam, MD, MBBSvenetoclaxrituximabVerified on source pageonlineprogram.hematology.org
- 370Oral presentationLck regulates RNA polymerase II-dependent AP-1/BCL-xl transcriptional programs and therapeutic response to dasatinib in T-cell acute lymphoblastic leukemia.Huanbin Zhao, PhDdasatinibS63845Verified on source pageonlineprogram.hematology.org
Multiple myeloma
30 verified · pulled 2026-11-11 · showing 0 headline abstractsOpen in Multiple myeloma →All ASH abstracts →- 115OralAnitocabtagene autoleucel following induction therapy in newly diagnosed multiple myeloma: Early safety, response, and MRD Results from the phase 2 GEM-anitofirst studyMaria-Victoria Mateos JrGEM-anitofirstanitocabtagene autoleucelVerified on source pageonlineprogram.hematology.org
- 116Oral
- 117Oral
- 118OralDeep and durable responses achieved with CB-011, an off-the-shelf CAR-T cell therapy, for heavily pretreated patients with relapsed/refractory multiple myeloma (CaMMouflage trial)Adriana RossiCaMMouflageCB-011Verified on source pageonlineprogram.hematology.org
- 119Oral
- 120OralGPRC5D expression and locus integrity in relapsed/refractory multiple myeloma treated with arlocabtagene autoleucel in a first-in-human Phase 1 trialSafiyyah Ziyadarlocabtagene autoleucelVerified on source pageonlineprogram.hematology.org